Shape Therapeutics, Inc.
- Biotech or pharma, therapeutic R&D
Shape Therapeutics is an AI-driven genomic medicines company focused on creating curative and transformative medicines through its programmable RNA editing technology. With backing from key investors including New Enterprise Associates and Decheng Capital, Shape is developing gene therapies to target prevalent human diseases, including Parkinson’s disease and ABCA4-driven diseases. Shape’s powerful RNA-based genetic editing platform, RNAFix delivers a guide RNA to recruit existing human ADAR proteins for precise RNA editing, while AAV.ai unlocks novel capsids for CNS and beyond as a best-in-class delivery system to the primate deep brain after IV administration. TruStable, Shape’s human cell line manufacturing platform, has the potential to be the new gold standard for AAV manufacturing as it has shown greater than 90x improvement in manufacturing compared to current lines. These three development pillars have positioned Shape to emerge as a leading name in gene therapy.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}